Profile picture

Doctor Martin Meyer

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
Membership: FESC Member
Follow
Biography
Medical doctor & PhD in cardiovascular medicine, with research focused on Phase II & III trials in post–cardiac arrest care. Special interest in modulating systemic inflammation to reduce organ injury and improve survival.
Logo ESC

Contributor content

Neurofilament light chain and neuron-specific enolase for estimating long-term cognitive function after cardiac arrest
Presentation
Neurofilament light chain and neuron-specific enolase for estimating long-term cognitive function after cardiac arrest
Systemic inflammatory response in cardiogenic shock patients randomized to microaxial flow pump or standard care in the DanGer-Shock trial
Presentation
Systemic inflammatory response in cardiogenic shock patients randomized to microaxial flow pump or standard care in the DanGer-Shock trial
Impact of oxygenations targets on inflammation after out-of-hospital cardiac arrest in males and females - a substudy of the BOX trial
Presentation
Impact of oxygenations targets on inflammation after out-of-hospital cardiac arrest in males and females - a substudy of the BOX trial
Influence of blood pressure targets on inflammation and associations between inflammatory markers and vasopressor usage after cardiac arrest - a substudy of a randomized clinical trial
Presentation
Influence of blood pressure targets on inflammation and associations between inflammatory markers and vasopressor usage after cardiac arrest - a substudy of a randomized clinical trial
Performance of neuron-specific enolase and neurofilament light chain in predicting death after hospital admittance from out-of-hospital cardiac arrest - A sub study of the IMICA trial
Presentation
Performance of neuron-specific enolase and neurofilament light chain in predicting death after hospital admittance from out-of-hospital cardiac arrest - A sub study of the IMICA trial
Tocilizumab mitigates hypercoagulability after out-of-hospital cardiac arrest - results from a randomized controlled trial (IMICA)
Presentation
Tocilizumab mitigates hypercoagulability after out-of-hospital cardiac arrest - results from a randomized controlled trial (IMICA)
Tocilizumab reduces cardiac injury after out-of-hospital cardiac arrest primarily in patients without acute revascularization - Results from a randomized trial, The IMICA trial
Presentation
Tocilizumab reduces cardiac injury after out-of-hospital cardiac arrest primarily in patients without acute revascularization - Results from a randomized trial, The IMICA trial

ESC 365 is supported by